|
Comparison of Low-dose Spiral Breast CT With MRI in Major Indications of MRI for Breast Diagnostics
RECRUITINGN/ASponsored by AB-CT - Advanced Breast-CT GmbH
Actively Recruiting
PhaseN/A
SponsorAB-CT - Advanced Breast-CT GmbH
Started2023-11-24
Est. completion2025-12
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05989022
Summary
Comparison between two diagnostic modalities for breast cancer diagnosis. Two different imaging systems are compared to evaluate the performance of the two systems
Eligibility
Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Sex: female 2. Age: at least 18 years 3. Inconclusive findings in conventional imaging or preoperative staging or evaluation of therapy response in the neoadjuvant chemotherapy setting or imaging of the breast after breast-conserving therapy or finding the cause of hemorrhagic nipple discharge or prosthesis imaging or screening of women with hereditary or familial increased risk for the development of breast cancer or axillary lymph node metastasis suspected to originate from breast tissue 4. Persons able and willing to understand and sign informed consent form Exclusion Criteria: 1. Known pregnancy or breastfeeding 2. Presence of BRCA1 or BRCA2 allele 3. Insufficient renal function (MDRD) 4. Dysfunction of the thyroid gland (TSH degradation) 5. Known allergy or intolerance against iodine-containing contrast enhancing agents or MRI contrast enhancing agents 6. Patients with paramagnetic or magnetic material inside the breast, claustrophobia
Conditions3
Breast CancerBreast Cancer DiagnosisCancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorAB-CT - Advanced Breast-CT GmbH
Started2023-11-24
Est. completion2025-12
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05989022